Aspirion has announced the acquisition of Boost Healthcare, bolstering its revenue cycle management (RCM) services and furthering its mission to secure rightful reimbursement for healthcare providers through technology solutions.
Boost Healthcare is an Alameda, California-based firm focused on helping healthcare providers identify and recover revenue. The Boost Healthcare team works to improve overall revenue by recovering denied and underpaid claims from commercial and government payers.
Aspirion is a RCM company that helps hospitals and physicians recover otherwise lost claims revenue from motor vehicle accidents, workers compensation, the Veteran’s Administration and Tricare as well as out-of-state Medicaid, Medicaid eligibility, underpayments and denials. Aspirion’s experienced team of healthcare, legal and technical professionals combined with industry-leading technology platforms help ensure that providers receive their Complex RCM revenue so that providers, hospitals, and their staff can focus on patient care. Chicago-based private equity firm Linden Capital Partners is a majority shareholder of Aspirion.
“Joining the Aspirion family marks an exciting new chapter for Boost Healthcare,” said Liana Hamilton, Founder and Managing Partner of Boost. “Our shared commitment to innovation and client success makes this partnership particularly powerful. Aspirion’s technological infrastructure and automation capabilities will amplify our ability to deliver best-in-class results, ensuring healthcare providers maintain the financial stability needed to serve their patients’ needs effectively.”
This marks Aspirion’s second RCM acquisition since it was acquired by Linden Capital Partners in June 2022. Last year, the company acquired Las Vegas, Nevada-based FIRM Revenue Cycle Management Services for an undisclosed price. The Boost Healthcare deal also marks Aspirion’s seventh transaction since 2018.
According to data captured in the LevinPro HC database, this acquisition represents the 238th eHealth transaction of 2024, and the 36th in the RCM specialty. There were 55 RCM deals announced during 2023, and 68 announced during 2022. Financial terms of the deal were not disclosed.
